Causes of death varied significantly between patients receiving ablative and non-ablative transplants. (Table 3 ) Among patients who died after receiving ablative conditioning, major causes included fungal infections (n ¼ 20), respiratory failure from diffuse alveolar damage or acute respiratory distress syndrome (n ¼ 8), acute GVHD (n ¼ 18), multi-organ failure (n ¼ 16), viral infections (n ¼ 13) and progressive disease (n ¼ 39). In contrast, only three patients receiving non-ablative transplants died of any of these causes. The major causes of death among recipients of nonablative transplants were mostly chronic GVHD (n ¼ 12) and progressive disease (n ¼ 50). At the time of last follow-up, August 2011, among 144 patients receiving ablative conditioning, 14 were alive a median of 15.1 years (3.6 --23.5) post transplant, of whom 6 had relapsed. Among 134 patients receiving non-ablative conditioning, 56 were alive a median of 7.1 years (2.9 --12.9) post transplant, of whom 25 had relapsed. At 2 years, the probabilities of non-relapse mortality were 18% and 55% for non-ablative and ablative regimens, respectively. At 6 years, the probabilities of relapse or disease progression were 55% and 34% for non-ablative and ablative regimens, respectively. For patients undergoing ablative allo-SCTs, the probabilities of OS and PFS are 11 and 8% at 15 years. For patients undergoing non-ablative transplants, the probabilities of OS and PFS are 39 and 16% at 10 years. (Figure 1 ) The best outcomes were found among 88 patients who received an autologous transplant, followed by a non-myeloablative allograft within 4 months of the autologous transplant and who had not progressed after a prior autologous transplant. (Figure 2 ) Their 10-year OS was 49% and PFS was 27%.